医学
肝硬化
内科学
胃肠病学
队列
丙型肝炎
慢性肝炎
活检
肝活检
免疫学
病毒
作者
Milan J. Sonneveld,Willem Pieter Brouwer,Henry LY Chan,Teerha Piratvisuth,Jidong Jia,Stefan Zeuzem,Yun‐Fan Liaw,Bettina E. Hansen,Hannah Choi,Cynthia Wat,Vedran Pavlovic,Anuj Gaggar,Qing Xie,Marı́a Buti,Robert J. de Knegt,Harry L.A. Janssen
标识
DOI:10.1016/s2468-1253(19)30087-1
摘要
Summary Background Ruling out the presence of cirrhosis is important for the management of chronic hepatitis B. We aimed to study and optimise the performance of two non-invasive indices for ruling out cirrhosis: the aspartate aminotransferase-platelet ratio index (APRI) and fibrosis score based on four factors (FIB-4). Methods We applied established cutoffs to rule in (APRI >2·00; FIB-4 >3·25) or rule out (APRI Findings In the derivation dataset (n=2926; of whom 1750 were Asian); 340 (12%) individuals had cirrhosis. The validation cohort consisted of 1034 individuals (of whom 575 were Asian), with 155 (15%) individuals with cirrhosis. Application of conventional cutoffs for FIB-4 in the derivation dataset yielded unclassifiable results in 686 (23%) individuals, and 139 (41%) of the 340 patients with cirrhosis were misclassified as having no cirrhosis. Similarly, conventional cutoffs for APRI in the derivation dataset yielded unclassifiable results in 706 (24%) individuals, and 153 (45%) were misclassified as having no cirrhosis. An APRI of 0·45 or less had sensitivity of 91·5%, an NPV of 95·4%, and misclassified 29 (9%) of 340 individuals with cirrhosis in the derivation dataset, but performance was reduced in the validation set (22 [14%] of 155 individuals with cirrhosis misclassified). A FIB-4 score of 0·70 had a sensitivity of 90·9%, an NPV of 96·6%, and misclassified 31 (9%) of individuals with cirrhosis in the derivation dataset. In the validation cohort, the same score gave a sensitivity of 94·2%, an NPV of 97·3%, and misclassified nine (6%) of the individuals with cirrhosis. Subgroup analysis indicated that the new FIB-4 cutoff performed acceptably in all subgroups except for individuals aged 30 years or younger. Interpretation Conventional cutoffs for APRI and FIB-4 should not be used to guide management of patients with chronic hepatitis B due to high rates of misclassification. A newly identified and externally validated cutoff for FIB-4 (≤0·70) can be used to exclude cirrhosis in patients over 30 years of age. Funding Foundation for Liver and Gastrointestinal Research, Rotterdam, Netherlands.
科研通智能强力驱动
Strongly Powered by AbleSci AI